高润霖，1941年生，籍贯河北唐山，心血管病学家，中国医学科学院阜外医院研究员，博士生导师。1959年9月考入北京医学院（现北大医学部）医学系，1965年8月毕业。1978年9月至 1981年12月在中国协和医科大学（现北京协和医学院）研究生院攻读硕士学位，从事心血管病学研究。1985年9月至1986年8月在美国罗马林达大学医学院进修介入心脏病学。1987年12月升为副研究员，1991年3月为研究员。1999年当选为中国工程院院士。

我国介入心脏病学先驱，率先在国内开展急性心肌梗死及并发心源性休克的急诊介入治疗和多项介入治疗新技术，致力于介入治疗再狭窄机制和预防研究，产学研结合，促进药物洗脱支架、可吸收药物洗脱支架创新及国产化。

皇冠足球90比分

1. Zheng JF#, Qiu H*, Tian Y, Hu XY, Luo T, Wu C, Tian Y, Tang Y, Song LF, Li L, Xu L, Xu B, and Gao RL*. Preclinical Evaluation of a Novel Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold in Porcine Coronary Artery at 6 Months. JACC Cardiovasc Interv. 2019;12(3):245-255.

2. Wang Z#*, Chen Z, Zhang L, Wang X, Hao G, Zhang Z, Shao L, Tian Y, Dong Y, Zheng C, Wang J, Zhu M, Weintraub WS, Gao R*; China Hypertension Survey Investigators. Status of Hypertension in China: Results From the China Hypertension Survey, 2012-2015. Circulation. 2018;137(22):2344-2356.

3. Tang Y#, Qiao S, Su X, Chen Y, Jin Z, Chen H, Xu B, Kong X, Pang W, Liu Y, Yu Z, Li X, Li H, Zhao Y, Wang Y, Li W, Tian J, Guan C, Xu B, and Gao R*; RESTORE SVD China Investigators. Drug-Coated Balloon Versus Drug-Eluting Stent for Small-Vessel Disease: The RESTORE SVD China Randomized Trial. JACC Cardiovasc Interv. 2018;11(23):2381-2392.

4. Xu B#, Gao R*, Yang Y, Cao X, Qin L, Li Y, Li Z, Li X, Lin H, Guo Y, Ma Y, Wang J, Nie S, Xu L, Cao E, Guan C, Stone GW; PANDA III Investigators. Biodegradable Polymer-Based Sirolimus-Eluting Stents With Differing Elution and Absorption Kinetics: The PANDA III Trial. J Am Coll Cardiol. 2016;67(19):2249-2258.

5. Xu B#, Redfors B, Yang Y*, Qiao S, Wu Y, Chen J, Liu H, Chen J, Xu L, Zhao Y, Guan C, Gao R*, and Généreux P. Impact of Operator Experience and Volume on Outcomes After Left Main Coronary Artery Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2016;9(20):2086-2093.

6. Xu B#, Qian J, Ge J, Wang J, Chen F, Chen J, Wei M, Chen Y, Yang Y, Gao R*, PEPCAD China ISR investigators. Two-year results and subgroup analyses of the PEPCAD China in-stent restenosis trial: A prospective, multicenter, randomized trial for the treatment of drug-eluting stent in-stent restenosis. Catheter Cardiovasc Interv. 2016;87 Suppl 1:624-9.

7. Gao R#*, Yang Y, Han Y, Huo Y, Chen J, Yu B, Su X, Li L, Kuo HC, Ying SW, Cheong WF, Zhang Y, Su X, Xu B, Popma JJ, Stone GW; ABSORB China Investigators. Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial. J Am Coll Cardiol. 2015;66(21):2298-2309.

8. Xu B#, Gao R*, Wang J, Yang Y, Chen S, Liu B, Chen F, Li Z, Han Y, Fu G, Zhao Y, Ge J; PEPCAD China ISR Trial Investigators. A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial. JACC Cardiovasc Interv. 2014;7(2):204-211.

9. Gao R#,Zhang J, Cheng L, Wu X, Dong W, Yang X, Li T, Liu X, Xu Y, Li X, and Zhou M*. A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol. 2010;55(18):1907-14.

10. Gao R#, Patel A, Gao W, Hu D, Huang D, Kong L, Qi W, Wu Y, Yang Y, Harris P, Algert C, Groenestein P, aTurnbull F*; CPACS Investigators. Prospective observational study of acute coronary syndromes in China: practice patterns and outcomes. Heart. 2008;94(5):554-60.